Morgan Stanley Aligos Therapeutics, Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,300 shares of ALGS stock, worth $27,059. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,300

Previous 3,300 -0.0%

Holding current value

$27,059

Previous $3,000 66.67%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 16, 2024	BUY	$0.64 - $1.13 $832 - $1,468	1,300 Added 65.0%	3,300 $3,000
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $832 - $1,468	1,300 Added 65.0%	3,300 $3,000
Q4 2023 Aug 16, 2024	SELL	$0.56 - $0.8 $728 - $1,040	-1,300 Reduced 39.39%	2,000 $1,000
Q3 2023 Nov 15, 2023	SELL	$0.71 - $1.06 $710 - $1,060	-1,000 Reduced 33.33%	2,000 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $115,454 - $176,424	-129,724 Reduced 97.74%	3,000 $2,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $113,422 - $275,082	130,371 Added 5540.63%	132,724 $115,000
Q4 2022 Feb 14, 2023	SELL	$0.89 - $28.0 $7,056 - $222,012	-7,929 Reduced 77.12%	2,353 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $44,870 - $1.16 Million	-42,331 Reduced 80.46%	10,282 $11,000
Q2 2022 Oct 27, 2022	SELL	$1.04 - $2.14 $28,596 - $58,843	-27,497 Reduced 34.32%	52,613 $64,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $28,596 - $58,843	-27,497 Reduced 34.32%	52,613 $64,000
Q1 2022 Oct 27, 2022	BUY	$2.08 - $12.2 $57,193 - $335,463	27,497 Added 52.26%	80,110 $171,000
Q1 2022 May 13, 2022	BUY	$2.08 - $12.2 $59,155 - $346,968	28,440 Added 55.04%	80,110 $171,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $4.8 Million - $7.39 Million	-417,734 Reduced 88.99%	51,670 $613,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $6.84 Million - $8.32 Million	469,404 New	469,404 $7.28 Million

Others Institutions Holding ALGS

# of Institutions

Shares Held

47.3M

Call Options Held

1.4K

Put Options Held

300

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $326M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account